HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Efficacy and safety of Micafungin in Febrile NeutropenicPatients Treated for Hematological Malignancies

Files in This Item:
IM46-1.pdf260.87 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Efficacy and safety of Micafungin in Febrile NeutropenicPatients Treated for Hematological Malignancies
Authors: Toubai, Tomomi Browse this author
Tanaka, Junji Browse this author →KAKEN DB
Ota, Shuichi Browse this author
Shigematsu, Akio Browse this author
Shono, Yusuke Browse this author
Ibata, Makoto Browse this author
Hashino, Satoshi Browse this author →KAKEN DB
Kondo, Takeshi Browse this author →KAKEN DB
Kakinoki, Yasutaka Browse this author
Masauzi, Nobuo Browse this author
Kasai, Masaharu Browse this author
Iwasaki, Hiroshi Browse this author
Kurosawa, Mitsutoshi Browse this author
Asaka, Masahiro Browse this author
Imamura, Masahiro Browse this author
Keywords: febrile neutropenia
fungal infection
empirical antifungal therapy
hematological malignancies
Issue Date: 2007
Publisher: The Japanese Society of Internal Medicine
Journal Title: Internal Medicine
Volume: 46
Issue: 1
Start Page: 3
End Page: 9
Publisher DOI: 10.2169/internalmedicine.46.6021
PMID: 17202726
Abstract: Objective: The purpose of this study was to prospectively evaluate the efficacy and safety of micafungin (MCFG) in empirical therapy for febrile neutropenic patients for whom antibiotic therapy was not effective for hematological malignancies. Patients and Methods: Twenty-three hematological patients aged 27-82 years with febrile neutropenia for whom antibiotic therapy was not effective were enrolled in this study and responses to treatment were evaluated. Results: Treatment success rate was 73.9%. Treatment success rates by primary diagnosis were 77.8% in patients with AML, 50.0% in patients with NHL and 87.5% in patients with other diseases. Moreover, MCFG at a dose of 100 mg or more have a tendency to be effective. One or more adverse events occurred in five (27.7%) of the patients during the study. All of these adverse events were below grade 2 toxicity. Conclusions: Although the number of patients studied was limited, MCFG as a monotherapy seems to be effective and safe as an empirical therapy in patients with febrile neutropenia. However, further investigation using large-scale studies is needed. This study demonstrated the clinical efficacy and safety of MCFG in patients with febrile neutropenia and with hematological malignancies.
Type: article (author version)
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 東梅 友美

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


Feedback - Hokkaido University